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Abstract Background: Although previous investigators
have established an association between blood transfusion
and adverse outcomes, the relative frequency of different
morbid events and the association with transfusion dose
are not well understood. Questions/Purposes: The purpose
of the study is to characterize the relationship between
blood transfusion and different types of morbidity after
posterior spine fusion. Methods: We retrospectively ana-
lyzed electronic medical records for 963 patients who
underwent posterior spinal fusion surgery at a single
institution, of which 603 (62.6%) received an allogeneic
blood transfusion. Then, we assessed patient and surgical
characteristics in a risk-adjusted fashion to identify various
morbid event rates and independent predictors in these adverse
outcomes. Results: Compared to the non-transfused patients,
transfused patients had a higher incidence of any morbid event
(9.1 vs. 2.5%. P < 0.0001), thrombotic events (4.6 vs. 1.1%,
P = 0.0025), and hospital-acquired infections (2.3 vs. 0.6%,
P = 0.039). Renal, respiratory, and ischemic morbidity
occurred less frequently and were not more common in trans-
fused patients. Risk-adjusted analysis revealed a dose-
response effect, whereby for each unit of allogeneic blood
transfused, the risks of any morbid event (OR 1.183; 95% CI
1.103–1.274; P < 0.0001), thrombotic complication (OR
1.104; 95% CI 1.032–1.194; P = 0.0035), and infectious com-
plication (OR 1.182; 95% CI 1.077–1.332; P = 0.0002) were
increased. Conclusion: Our data demonstrate risk-adjusted
and transfusion dose-related increases in perioperative mor-
bidity, with thrombotic and infectious events being the most
common.
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Introduction
Spinal fusion is among the top 10 surgical procedures
associated with blood transfusion [27], and the utilization
of blood for this procedure is increasing [33]. Despite its
widespread use, blood transfusion is not without risks [1].
Perioperative blood transfusion has been associated with
hospital-acquired infection, [1, 16, 24, 25, 28, 32], and
this finding was recently demonstrated in a meta-analysis
of randomized trials [24], where a liberal transfusion strat-
egy was a risk for infection, especially in orthopedic
surgery patients.
Although the relationship between transfusion and in-
fection after spine surgery has been established, the asso-
ciation of transfusion with other complications is unclear
[16, 25, 32]. For example, in a retrospective analysis of
300 patients undergoing spine surgery with substantial
blood loss, blood transfusion was associated only with
surgical site infection, and not with other complications;
however, it is important to note that the authors included
very few noninfectious complications in their analysis
[22]. In contrast, a large database analysis revealed that
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even low-dose blood transfusion (even 1 unit) conferred
an increased risk of any major or minor complication after
elective spine surgery [28]. However, the authors did not
provide data on the incidence of individual complications,
and Bmajor^ complications varied widely by definition,
from postoperative wound breakdown to coma. Larger
sample sizes with detailed perioperative data are necessary
to assess the relationship between transfusion and nonin-
fectious complications. Additionally, most previous stud-
ies have used broad primary outcomes, such as Bmajor
complications^ or Bany perioperative complication,^
which precludes any analysis of the relationship between
transfusion and specific morbid event rates.
A better understanding of the risk-benefit balance be-
tween anemia, transfusion, and clinical outcomes after
spinal fusion is necessary to optimize clinical outcomes
and reduce healthcare costs [10]. Such a risk-benefit anal-
ysis is especially important because transfusion is the
most common procedure performed in US hospitals [12],
and the Joint Commission has determined that transfusion
is one of the top five overused procedures [18]. The
purpose of this study was to determine (1) if perioperative
red blood cell (RBC) transfusion is associated with post-
operative morbidity (including noninfectious complica-
tions) and (2) if a dose-response relationship exists
between transfusion and the likelihood of developing
these complications.
Patients and Methods
After receiving approval from the institutional review board
at our institution, we acquired electronic medical record data
from a web-based intelligence portal (IMPACT Online,
Haemonetics Corp., Braintree, MA), our hospital billing
database (Datamart), and the anesthesia information man-
agement system (Metavision; iMdSoft, Dedham, MA) for
patients who were discharged from our institution between
January 2009 and January 2015. Current Procedural
Terminology (CPT) codes were queried to identify consec-
utive patients who underwent posterior spinal fusion sur-
gery. CPT codes included were 22612, 22630, 22633,
22800, 22802, and 22804 (Table 1). Only patients over the
age of 18 were included in the analysis.
Our use of these databases and our quality control methods
have been described previously [8, 9]. Collected data included
up to 29 pre-hospital comorbidities for each patient that were
used to determine the Charlson Comorbidity Index [4], the
number of vertebral levels surgically fused, the number of
allogeneic RBC units each patient received throughout the
hospitalization, amount of autologous blood transfused intra-
operative, length of stay, estimated blood loss, nadir hemoglo-
bin during hospitalization, and duration of surgery. Vertebral
levels were dichotomized into two groups: less than or equal to
three levels and greater than three levels.
In-hospital morbid events were determined by ICD-9
codes upon discharge, as we have described previously [26,
30]. Outcomes of interest included transient ischemic attack
(TIA), cerebrovascular attack (CVA), myocardial infarction
(MI), ventilator-associated pneumonia, kidney injury, postop-
erative infection, sepsis, drug-resistant infection, Clostridium
difficile infection, deep venous thrombosis (DVT), pulmonary
embolism (PE), and disseminated intravascular coagulation
(DIC). Postoperative infection includes a postoperative uri-
nary tract infection, a surgical site infection, pneumonia, or
other infectious complications occurring in the postoperative
period. A thrombotic event was defined as one or more of the
following: DIC, DVT, or PE. A hospital-acquired infection
was defined as one or more of the following: postoperative
infection, sepsis, drug-resistant infection, or C. difficile infec-
tion. An ischemic event was defined as one or more of the
following: TIA, CVA, or MI. These groupings were not mu-
tually exclusive, for instance, a patient could have both a TIA
and an MI but that would only count as one ischemic event.
Chi-squared and Fisher’s exact tests were used to com-
pare dichotomous variables, and Student’s t test was used to
analyze continuous variables. The Wilcoxon rank sum test
was used to analyze data that were not normally distributed.
Normality was tested with the Shapiro-Wilk test. Risk for
transfusion and perioperative morbidity were analyzed in
both an unadjusted and risk-adjusted fashion by univariable
and multivariable logistic regressions, respectively.
Variables entered into the logistic regression model include
those clinical factors that have been shown in previous
studies to be associated with adverse outcomes, and those
factors that were associated with morbidity upon univariate
testing in the current study. Estimated blood loss was entered
as quartiles since as a continuous variable the interaction
between RBCs transfused and estimated blood loss rendered
the model unstable. Continuous variables that were normally
distributed are presented as mean ± SD, whereas other vari-
ables are presented as median (interquartile range). P < 0.05
(by two-tailed tests) was used to define significance. Non-
adjusted and risk-adjusted odds ratios (ORs) and 95% con-
fidence intervals (CIs) are reported. Analyses were generat-
ed with JMP version 12 (SAS Institute, Inc., Cary, NC).
Results
One thousand five hundred sixty-three patients had a CPT
codewhich indicated a procedure that included a type of spinal
fusion (Table 1). Six hundred patients were excluded for age
<18 years. Nine hundred sixty-three patients were included in
our analysis. The cohort had slightly more women (N = 553,
Table 1 Description of CPT codes
CPT code CPT code description
22612 Posterolateral fusion, lumbar (first segment)
22630 Posterior interbody fusion, lumbar
22633 Combined fusion, posterolateral fusion, with posterior
interbody fusion
22800 Arthrodesis, posterior, for spinal deformity; less than or
equal to 6 vertebral segments
22802 Arthrodesis, posterior, for spinal deformity; 7 to 12
vertebral segments
22804 Arthrodesis, posterior, for spinal deformity; 13 or more
vertebral segments
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57.4%) than men, and the average age was 56 ± 16 years
(Table 2). The median estimated surgical blood loss was
800 mL (400, 1,400). Only 4.6% of our cohort received
tranexamic acid, as this medication was only recently ap-
proved for select cases at our institution. The transfused group
of patients had longer surgeries and more blood loss.
A total of 603 patients (62.6%) received a blood trans-
fusion, with 419 (43.5%) receiving blood intraoperatively,
499 (51.8%) receiving blood postoperatively, and 311
(32.3%) receiving blood during both time periods. Of the
963 patients included in the analysis, 505 (52.4%) were on
the orthopedic surgery service and 458 (47.6%) were on the
neurosurgery service. In the univariate analysis, significant
predictors of transfusion were increased age (P < 0.0001),
increased Charlson score (P < 0.0001), female sex
(P < 0.0001), increased estimated blood loss (P < 0.0001),
and increased surgical time (P < 0.0001) (Table 2).
Compared with the non-transfused patients, transfused
patients had a higher incidence of any morbid event (9.1 vs.
2.5%. P < 0.0001), thrombotic events (4.6 vs. 1.1%, P =
0.0025), and hospital-acquired infections (2.3 vs. 0.6%,
P = 0.039) (Table 3). Renal, respiratory, and ischemic mor-
bidity occurred less frequently and had similar rates in
transfused and non-transfused patients (renal morbidity 1.5
vs. 1.1%; P = 0.78; respiratory morbidity: 0.7 vs. 0%; P =
0.3; ischemic morbidity: 0.7 vs. 0%; P = 0.3).
The association between allogeneic blood transfusion and
perioperative morbidity (any morbid event) was assessed by
univariable and multivariable analyses (Table 4). Univariable
analysis showed that increasing Charlson score, vertebral
levels fused, estimated blood loss, surgical time, and number
of RBC units were associated with an increased risk of occur-
rence of any perioperative morbid event. In the multivariable
analysis, after controlling for age, sex, race, Charlson score,
BMI, number of vertebral levels, estimated blood loss, and
surgical duration, increased allogeneic RBC transfusion (OR
1.183 per unit; 95% CI 1.103–1.274), and increased Charlson
score (OR 1.166 per point; 95% CI 1.004–1.339) were asso-
ciated with an increased risk of perioperative morbidity (the
occurrence of any morbid event).
The relative occurrence rates of the different morbid events
are shown according to the transfusion dose in Fig. 1. It is
notable that a dose of 1–2 RBC units was not associated with a
change in morbid event rates, but a dose of ≥3 RBC units was
a threshold at which morbidity increased significantly.
Overall, thrombotic complications occurred in 3.3% of all
patients. These thrombotic complications were relatively
evenly distributed among DIC, DVT, and PE, as all three types
of thrombotic event increased with increasing transfusion dose
(Fig. 2). Overall, infectious complications occurred in 1.7% of
all patients and increased in frequency with increasing trans-
fusion dose (Figs. 1 and 3). These infections included 12
surgical site infections, two cases of sepsis, one drug-
resistant infection, and one case of C. difficile. Renal compli-
cations occurred with an overall frequency of 1.4%, and
ischemic and respiratory morbid events occurred with an
overall frequency of less than 1%. Ischemic, respiratory, and
renal morbid events, despite being less likely, tended to in-
crease with increasing dose of RBC transfused, demonstrating
a possible dose-response relationship (Fig. 4)
In a risk-adjusted multivariable analysis controlling for
age, sex, race, Charlson score, body mass index, levels fused,
intraoperative blood loss, and surgical duration, RBC transfu-
sion dose (per unit) was independently associated with an
increased odds of any infection (OR 1.182; 95% CI 1.077–
1.332; P = 0.0002), and increased odds of a thrombotic event
(OR 1.104; 95% CI 1.032–1.194; P = 0.0035).
Discussion
Our findings demonstrate that allogeneic RBC transfusion is
associated with a dose-dependent increased risk for infectious
and thrombotic complications spinal fusion, even after risk-








Age, mean ± SD 56 ± 16 59 ± 15 52 ± 16 <0.0001
Male (%) 410 (42.6) 215 (35.7) 194 (54.1) <0.0001
Race (%) 0.07
Caucasian 737 (76.5) 456 (75.6) 281 (78.1)
African American 131 (13.6) 93 (15.4) 38 (10.6)
Other 95 (9.9) 54 (9) 41 (11.4)
Tranexamic acid use (%) 44 (4.6) 27 (4.5) 17 (4.7) 0.87
Charlson score (median, IQR) 1 (0, 2) 1 (0, 2) 0 (0, 1) <0.0001
BMI 28.4 (24.5, 32.7) 28.4 (24.4, 33.0) 28.5 (24.7, 32.3) 0.43
Nadir hemoglobin 8.9 ± 1.4 8.2 ± 0.9 10 ± 1.3 <0.0001
>3 vertebral level fusions (%) 387 (40.2) 303 (50.3) 84 (23.3) <0.0001
Estimated blood loss (mL) 800 (400, 1,400) 1,100 (700, 1,700) 400 (300, 700) <0.0001
Surgical time (hr) 5.7 (4.4, 7.2) 6.5 (4.9, 8) 4.8 (3.9, 4.9) <0.0001
Autologous blood (mL) 109 ± 241 165 ± 287 17 ± 74 <0.0001
BMI body mass index, IQR interquartile range, SD standard deviation, mL milliliters, min minutes
aTransfused allogeneic blood
bDifference between transfused and not transfused groups
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adjustment for other known predictors of perioperative mor-
bidity. As the rate of spinal fusion surgery increases in the
USA, particularly among older patients [21], understanding
the relationship between transfusion and clinical outcomes is
relevant to optimizing clinical care while reducing costs [10].
Although the association between transfusion and infection
after spine procedures has been described previously [16, 25,
32], to our knowledge, this study is the first to investigate
noninfectious outcomes and the relationship between transfu-
sion and these complications.
Potential limitations in our study include the retrospec-
tive observational design, which is only able to suggest
association not causation. To increase the validity of our
findings we controlled for potential confounders, such as
intraoperative blood loss, number of spinal fusion levels,
operative time, and comorbid conditions. After such risk-
adjustment, transfusion remained a dose-dependent indepen-
dent predictor of morbid events; however, other unrecog-
nized confounding variables remain a potential limitation.
Of note, our transfusion rate of 63% is much higher than has
been previously reported in previous studies [27]. This can
be possibly attributed to a number of factors: (1) as a
tertiary-care center, some of our patients may have been
sicker with a greater comorbidity burden, (2) tranexamic
acid use was not approved for use at our institution for the
majority of this study, and (3) most studies reporting lower






Any morbid event, n (%) 55 (9.1) 9 (2.5) <0.0001
Infection, n (%) 14 (2.3) 2 (0.6) 0.04
Sepsis 2 (0.3) 0 (0) 0.53
SSI 10 (1.7) 2 (0.6) 0.23
Drug-resistant infection 1 (0.2) 0 (0) 0.99
Clostridium difficile 1 (0.2) 0 (0) 0.99
Thrombotic complication, n (%) 28 (4.6) 4 (1.1) 0.003
Deep venous thrombosisa 13 (2.2) 1 (0.3) 0.02
Pulmonary embolisma 15 (2.5) 2 (0.5) 0.04
DIC 6 (1) 1 (0.3) 0.27
Renal complication, n (%) 9 (1.5) 4 (1.1) 0.78
Respiratory complication n (%) 4 (0.7) 0 (0) 0.3
Ischemic event, n (%) 4 (0.7) 0 (0) 0.3
Death, n (%) 1 (0.2) 0 (0) 0.99
SSI surgical site infection, DIC disseminated intravascular coagulation
a Six patients had a deep venous thrombosis and pulmonary embolism
Table 4 Risk factors for perioperative morbiditya
Univariable Multivariableb
OR (95% CI) P value OR (95% CI) P value
Age 1.009 (0.986–1.034) 0.3 0.999 (0.981–1.019) 0.95
Male sex 1.053 (0.503–2.162) 0.84 0.886 (0.485–1.596) 0.69
Patient race
Caucasian 1.00 (reference) 1.00 (reference)
African American 0.955 (0.274–2.581) 0.91 1.211 (0.5, 2.63) 0.65
Other 1.536 (0.469–4.07) 0.28 2.11 (0.813–4.922) 0.12
Charlson score 1.299 (1.088–1.533) <0.0001 1.166 (1.004–1.339) 0.045
Body mass index 1.003 (0.943–1.065) 0.88 1 (0.956–1.045) 0.99
Number of levels (>3 vs ≤3) 2.598 (0.128, 5.815) 0.003 1.511 (0.807–2.852) 0.2
Estimated blood lossc 1.533 (1.195, 1.989) 0.0007 0.937 (0.65–1.247) 0.72
Surgical duration (hours) 1.224 (1.102, 1.357) 0.0002 1.026 (0.878–1.193) 0.74
RBC unitsd 1.188 (1.094–1.293) <0.0001 1.183 (1.103–1.274) <0.0001
RBC red blood cell
a Perioperative morbidity includes having at least one of the following morbid events: transient ischemic attack, cerebrovascular attack,
myocardial infarction, ventilator-associated pneumonia, kidney injury, surgical site infection, sepsis, drug-resistant infection, Clostridium
difficile infection, deep venous thrombosis, pulmonary embolism, and disseminated intravascular coagulation
b Independent variables in the model included age, sex, race, Charlson score, body mass index, surgical service, number of levels, estimated blood
loss (as quartiles), and surgical duration
cModeled in quartiles—(1) <400 mL, (2) 400–800 mL, (3) 800–1400 mL, and (4) >1400 mL
dRBC units as a continuous variable (Odds ratio is effect per unit transfused)
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transfusion figures look at intraoperative transfusion while
we looked at perioperative transfusion. Additionally, the use
of ICD-9 codes to determine morbid events may be less
reliable than prospectively collected outcome data. For in-
stance, all of our postoperative infections are grouped such
as UTI, surgical site infection and pneumonia with no ability
to distinguish them. It is unlikely, however, that such errors
would occur in a biased fashion that would influence the
primary findings. Another potential limitation of this study
is that it represents transfusion practice at one large academ-
ic referral center. Therefore, our cohort may not be repre-
sentative of all individuals at all facilities undergoing spine
arthrodesis.
The relationship between transfusion and thrombotic
events has direct clinical and economic implications, as
average hospital costs are $30,587 greater in patients who
develop a DVT after spine fusion than in those who do not
[7]. Furthermore, this relationship between transfusion and
thrombotic complications may aid clinical decision-making,
especially as the use of antifibrinolytic medications becomes
more common in spine surgery [5]. The thrombotic compli-
cations in our cohort do not appear to be attributed to such
medications, for of the 44 patients that received tranexamic
acid in our cohort, no thrombotic events occurred. It is
possible, however, that we may have underestimated the
incidence of thrombotic events if antifibrinolytics had been
used with greater frequency, as there are no adequately
powered studies to date, proving that this class of drugs
does not predispose patients to thrombosis [20].
It has been postulated that transfusion of banked blood










































Fig. 1. Transfusion dose-response relationship for specific morbid
events, including thrombotic, infectious, and other (ischemic, renal,
or respiratory) complications. *P < 0.05 in comparison to patients who








































Fig. 2. Transfusion dose-response relationship across multiple trans-
fusion doses for specific thrombotic morbidities, including pulmonary
embolism (PE), deep venous thrombosis (DVT), and disseminated





































Fig. 3. Transfusion dose-response relationship across multiple trans-
fusion doses for specific infectious morbidities, including drug-
resistant infection, sepsis, Clostridium difficile, and postoperative in-





































Fig. 4. Transfusion dose-response relationship across multiple trans-
fusion doses for ischemic (stroke, transient ischemic attack, or
myocardial infarction), respiratory, and renal complications. RBC
red blood cells.
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adherence and aggregability of RBCs after storage [15].
These effects may become even more relevant because spine
surgery patients do not routinely receive preoperative throm-
boembolic chemoprophylaxis, as the risks of bleeding and
neurologic compromise from spinal hematoma are thought
to outweigh the benefits of prophylactic anticoagulants. For
these reasons, the judicious and timely use of postoperative
anticoagulants, as well as other methods such as mechanical
compression devices, plays an important role.
Like findings reported previously in the literature, our
data show a significant association between perioperative
blood transfusion and infectious complications after poste-
rior spinal fusion [16, 25, 32]. Further, the dose-response
relationship observed between transfusion volume and in-
fection risk in our cohort is consistent with the findings of
Woods et al. [32]. The larger impact identified in their cohort
as compared with that in our study may reflect differences in
their case and control populations, as the patients with
infection had significantly lower preoperative hemoglobin
levels and significantly greater intraoperative blood loss than
did the controls. In our cohort, transfusion dose was associ-
ated with infection, even after risk-adjusting for these and
other potentially confounding variables.
A variety of immuno-suppressive mechanisms have been
proposed to explain the link between allogeneic transfusion
and postoperative infection, including decreased CD4 and
interleukin 2 (IL-2) receptor-positive helper cells, increased
CD8 suppresser cells, decreased natural killer cells, in-
creased numbers of B cells, decreased IL-2 production, and
increased prostaglandin E2 production [2, 6, 17].
Transfusion-related immunomodulation (TRIM) is one of
the most widely accepted theories to explain the proinflam-
matory and immunosuppressive effects associated with
transfusion. TRIM describes a Btwo-insult^ model wherein
the first insult is the patient’s underlying inflammatory con-
dition from surgery and illness and the second insult is
triggered by the transfusion through the above-mentioned
effects [29]. Support for the premise that hospital-acquired
infection risk decreases with a more restrictive transfusion
strategy is most clearly demonstrated in a recent meta-
analysis of 18 prospective randomized trials [24]. The anal-
ysis showed an odds ratio of 0.82 for all patients and 0.70 for
the subgroup of orthopedic surgery patients, supporting the
decreased risk of hospital-acquired infection with a restric-
tive transfusion strategy. This is perhaps the strongest evi-
dence yet to link transfusion and infection risk, as the
authors included only randomized trials, thus minimizing
confounding by indication, which is common in transfusion
studies.
In general, restrictive transfusion practices are supported
by multiple randomized trials, [3, 11, 13, 14, 19, 23, 31] but
the role of restrictive transfusion during spine surgery spe-
cifically has not been determined because this patient pop-
ulation tends to have active and ongoing bleeding [22, 32].
Thus, we cannot strongly support or refute restrictive trans-
fusion thresholds during spine fusion. Perhaps the most
relevant prospective trial was that by Carson et al. [3] in a
population of elderly hip fracture patients with a high prev-
alence of cardiovascular disease. They found no
improvement in morbidity or mortality, or even in the ability
to ambulate after surgery, with a Hb transfusion trigger of
10 g/dL, compared with a trigger of 8 g/dL. However, their
study focused on the postoperative rather than the intraop-
erative period, when patients are less likely to have active
bleeding.
To our knowledge, this study represents the largest series
to date to examine the association between blood transfusion
and noninfectious outcomes after spine fusion. Our findings
offer new insights into the risk-benefit balance between
anemia, transfusion, and outcomes, and may help inform
clinical decision-making. By identifying transfusion as a risk
factor for thrombosis and infections, our results may serve to
heighten clinician awareness to optimize prevention, diag-
nosis, and treatment of these complications and thereby
improve outcomes after spinal fusion.
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